DelveInsight added a report on the “Parkinson’s Disease Levodopa Induced Dyskinesia Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Parkinson’s disease Levodopa Induced Dyskinesia. The launch of emerging therapies will significantly impact the Parkinson’s disease Levodopa Induced Dyskinesia market.
Parkinson’s Disease Levodopa Induced Dyskinesia Overview
Parkinson’s disease (PD) is a type of movement disorder that can affect the ability to perform common, daily activities. The most common motor symptoms of PD are tremor (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia).
Some of the key highlights of the Parkinson’s Disease Levodopa Induced Dyskinesia Market Report
- According to DelveInsight’s analysis, males are more prominent for developing PD in comparison to female.
- Among all the PD patients with different complications, LID accounts for higher number of cases.
- The rate of LID development is from 3 to 94%. The prevalence of LID mainly depends on age at onset, disease duration, and severity, and duration of levodopa therapy.
- Parkinson’s Disease Levodopa Induced Dyskinesia companies included such as Kyowa Kirin, Adamas Pharmaceuticals, Neurocrine Biosciences/Voyager Therapeutics, VistaGen Therapeutics, and several others.
- Parkinson’s Disease Levodopa Induced Dyskinesia drugs included such as Istradefylline (KW6002), Gocovri, VY-AADC, AV-101, and several others.
Download Sample Report @ Parkinson’s Disease Levodopa Induced Dyskinesia Market Share
Parkinson’s Disease Levodopa Induced Dyskinesia Epidemiology Segmentation
- Total Diagnosed Prevalent Pool
- Diagnosed Prevalent Pool
- Treatable Patient Pool
Parkinson’s Disease Levodopa Induced Dyskinesia Treatment
Treatment of LID requires careful history taking and clinical examination to find the type of dyskinesia as different approach is required for different types. Changes in dopaminergic medication including continuous dopaminergic stimulation are very helpful in the management of peak-dose dyskinesia.
Parkinson’s Disease Levodopa Induced Dyskinesia Types
Different types of surgical approaches including unilateral pallidotomy and deep brain stimulation have given very good result in patients, who cannot be managed by medications alone.
Parkinson’s Disease Levodopa Induced Dyskinesia Market Insights
The initial treatment with levodopa had lower incidences of freezing, somnolence, and edema. CALM-PD trial showed significant less number of PD patients with dyskinesia who took pramipexole in comparison to levodopa. However, the Movement Disorder Society evidence-based review panel concluded that there wasinsufficient evidence to support the use of pramipexole extended release to delay or treat LID.
Parkinson’s Disease Levodopa Induced Dyskinesia Emerging Therapy Assessment
The treatment strategy for PD-LID includes identifying the kind of dyskinesia and tailoring treatment accordingly. Some pharmaceutical and biotech companies like Neurocrine Biosciences/Voyager Therapeutics, VistaGen Therapeutics, Prilenia Therapeutics and others are researching new therapies that target PD-LID.
Parkinson’s Disease Levodopa Induced Dyskinesia Market Drivers
- Development of Adherence-Friendly Drug Formulations
- Development of Drug for Better Treatment of Motor Symptoms
- Gene Therapy and Stem Cell Therapy
Parkinson’s Disease Levodopa Induced Dyskinesia Market Barriers
- Inadequate Knowledge of Pathophysiology
- Lack of Diagnostic Measures and Methods
- Lack of Efficacy of Existing Therapies
Get in-depth information about Parkinson’s disease Levodopa Induced Dyskinesia Market Size
Table of content
1. Key Insights
2. Executive Summary of Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
3. Competitive Intelligence Analysis for Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
4. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID): Market Overview at a Glance
5. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID): Disease Background and Overview
6. Patient Journey
7. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) Unmet Needs
10. Key Endpoints of Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) Treatment
11. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) Marketed Products
12. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) Emerging Therapies
13. Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Parkinson’s disease Levodopa-Induced Dyskinesia (PD-LID)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/